|Bid||4.30 x 800|
|Ask||5.00 x 900|
|Day's Range||4.6800 - 4.9700|
|52 Week Range||3.6000 - 14.6250|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.57|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! James Noble became the CEO of AdaptimmuneRead More...
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the.
The big shareholder groups in Adaptimmune Therapeutics plc (NASDAQ:ADAP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.